Abstract:
:The new therapeutic options available to clinicians treating dyslipidaemia in the last decade have enabled effective treatment for many patients. The development of the HMG-CoA reductase inhibitors (statins) have been a major advance in that they possess multiple pharmacological effects (pleiotropic effects) resulting in potent reductions of low density lipoproteins (LDL) and prevention of the atherosclerotic process. More recently, the newer fibric acid derivatives have also reduced LDL to levels comparable to those achieved with statins, have reduced triglycerides, and gemfibrozil has been shown to increase high density lipoprotein (HDL) levels. Nicotinic acid has been made tolerable with sustained-release formulations, and is still considered an excellent choice in elevating HDL cholesterol and is potentially effective in reducing lipoprotein(a) [Lp(a)] levels, an emerging risk factor for coronary heart disease (CHD). Furthermore, recent studies have reported positive lipid-lowering effects from estrogen and/or progestogen in postmenopausal women but there are still conflicting reports on the use of these agents in dyslipidaemia and in females at risk for CHD. In addition to lowering lipid levels, these antihyperlipidaemic agents may have directly or indirectly targeted thrombogenic, fibrinolytic and atherosclerotic processes which may have been unaccounted for in their overall success in clinical trials. Although LDL cholesterol is still the major target for therapy, it is likely that over the next several years other lipid/lipoprotein and nonlipid parameters will become more generally accepted targets for specific therapeutic interventions. Some important emerging lipid/lipoprotein parameters that have been associated with CHD include elevated triglyceride, oxidised LDL cholesterol and Lp(a) levels, and low HDL levels. The nonlipid parameters include elevated homocysteine and fibrinogen, and decreased endothelial-derived nitric oxide production. Among the new investigational agents are inhibitors of squalene synthetase, acylCoA: cholesterol acyltransferase, cholesteryl ester transfer protein, monocyte-macrophages and LDL cholesterol oxidation. Future applications may include thyromimetic therapy, cholesterol vaccination, somatic gene therapy, and recombinant proteins, in particular, apolipoproteins A-I and E. Non-LDL-related targets such as peroxisome proliferator-activating receptors, matrix metalloproteinases and scavenger receptor class B type I may also have clinical significance in the treatment of atherosclerosis in the near future. Before lipid-lowering therapy, dietary and lifestyle modification is and should be the first therapeutic intervention in the management of dyslipidaemia. Although current recommendations from the US and Europe are slightly different, adherence to these recommendations is essential to lower the risk of atherosclerotic vascular disease, more specifically CHD. New guidelines that are expected in the near future will encompass global opinions from the expert scientific community addressing the issue of target LDL goal (aggressive versus moderate lowering) and the application of therapy for newer emerging CHD risk factors.
journal_name
Drugsjournal_title
Drugsauthors
Chong PH,Bachenheimer BSdoi
10.2165/00003495-200060010-00005subject
Has Abstractpub_date
2000-07-01 00:00:00pages
55-93issue
1eissn
0012-6667issn
1179-1950journal_volume
60pub_type
杂志文章,评审相关文献
DRUGS文献大全abstract::Chlamydia trachomatis infections are exceedingly prevalent, and can be associated with significant sequelae. The major infections are urethritis, cervicitis, salpingitis, and ocular infection. Chlamydial genital infections present as syndromes, where C. trachomatis is one of the causes of the syndrome. Because specifi...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-198427050-00005
更新日期:1984-05-01 00:00:00
abstract:UNLABELLED:Ceftriaxone is a parenteral third-generation cephalosporin with a long elimination half-life which permits once-daily administration. It has good activity against Streptococcus pneumoniae, methicillin-susceptible staphylococci, Haemophilus influenzae, Moraxella catarrhalis and Neisseria spp. Although active ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200262070-00005
更新日期:2002-01-01 00:00:00
abstract::The annual incidence of skin and soft tissue infections (SSTIs) has nearly tripled in the US since the early 1990s. Many purulent SSTIs in the community setting are caused by methicillin-resistant Staphylococcus aureus (MRSA). Incision and drainage (I&D) are indicated for most purulent MRSA infections; however, the us...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/11599510-000000000-00000
更新日期:2012-02-12 00:00:00
abstract::86 patients with a first myocardial infarction presenting within 6 hours of the onset of symptoms were randomly allocated to treatment with intravenous streptokinase or anisoylated plasminogen streptokinase activator complex (APSAC). Plasma concentrations of fibrinogen, plasminogen, alpha 2-antiplasmin and fibrinogen ...
journal_title:Drugs
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.2165/00003495-198700333-00046
更新日期:1987-01-01 00:00:00
abstract::Stroke is the third most common cause of death in the US. Primary prevention of stroke can be achieved by control of risk factors including hypertension, diabetes mellitus, elevated cholesterol levels and smoking. Approximately one-third of all ischaemic strokes occur in patients with a history of stroke or transient ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200565040-00003
更新日期:2005-01-01 00:00:00
abstract::Glucocorticoids (GCs) are often used for improvement of quality of life, particularly in the elderly, but long-term GC use may cause harm; bone loss and fractures are among the most devastating side effects. Fracture risk is particularly high in patients with a severe underlying disease with an urgent need for treatme...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-019-01145-6
更新日期:2019-07-01 00:00:00
abstract::Immunotherapeutic approaches have been, and continue to be, aggressively investigated in the treatment of infiltrating gliomas. While the results of late-phase clinical studies have been disappointing in this disease space thus far, the success of immunotherapies in other malignancies as well as the incremental gains ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-019-01203-z
更新日期:2019-11-01 00:00:00
abstract::Peripheral arterial occlusive disease is a common condition with possible serious consequences. It is usually diagnosed at the intermittent claudication stage. There are 2 objectives of treatment: to prevent ischaemic attacks and to improve quality of life. Treatment efficacy is, however, usually evaluated only in ter...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199856003-00004
更新日期:1998-01-01 00:00:00
abstract::Avapritinib (AYVAKIT™) is a potent and selective tyrosine kinase inhibitor of platelet-derived growth factor receptor alpha (PDGFRA) and KIT activation loop mutants. It is being developed by Blueprint Medicines for the treatment of gastrointestinal stromal tumours (GIST), solid tumours and systemic mastocytosis. Avapr...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-020-01275-2
更新日期:2020-03-01 00:00:00
abstract::It is well documented that long term treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) increases the risk of peptic ulcer and that gastroduodenal mucosal erosions can be demonstrated in volunteers within 1 week of treatment initiation. However, long term studies in nonsurgical patients have not documented g...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199200445-00006
更新日期:1992-01-01 00:00:00
abstract::Nateglinide is a novel D-phenylalanine derivative that inhibits ATP-sensitive K+ channels in pancreatic beta-cells in the presence of glucose and thereby stimulates the prandial release of insulin. Nateglinide reduces fasting and mealtime blood glucose levels in animals, healthy volunteers, and patients with type 2 (n...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200060030-00007
更新日期:2000-09-01 00:00:00
abstract::Aminoglycosides are potent water-soluble antibiotics, with peak concentration-dependent bactericidal activity against many pathogenic aerobic Gram-negative bacilli and Staphylococcus aureus. For systemic therapy, they must be given parenterally (intravenously or intramuscularly). In the body they remain largely extrac...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199447060-00004
更新日期:1994-06-01 00:00:00
abstract::Echinocandins are a new class of antifungal agents with a novel mechanism of action (interference with fungal cell wall synthesis). Caspofungin (Cancidas), Caspofungin MSD) is the first echinocandin to be approved and is administered intravenously. Caspofungin 50 mg/day had similar efficacy to intravenous fluconazole ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200363200-00008
更新日期:2003-01-01 00:00:00
abstract::Trigeminal neuralgia is a representative neuropathic facial pain condition, characterised by unilateral paroxysmal pain in the distribution territory of one or more divisions of the trigeminal nerve, triggered by innocuous stimuli. A subgroup of patients with trigeminal neuralgia [TN (previously defined as atypical TN...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-018-0964-9
更新日期:2018-09-01 00:00:00
abstract::This article reviews the development and pharmacokinetics of a number of new dosage formulations (e.g. transdermal patches and buccal tablets) and new active substances (e.g. isosorbide 5-mononitrate) which have recently been introduced to overcome some of the problems inherent in conventional formulations of organic ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198700334-00006
更新日期:1987-01-01 00:00:00
abstract::Systemic therapy for advanced non-small cell lung cancer (NSCLC) has evolved over the last two decades, with modest improvements in quality of life and overall survival. A plateau has been reached with traditional chemotherapy, and efforts are now being directed at developing molecularly targeted agents. To date, thre...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/11532200-000000000-00000
更新日期:2010-01-01 00:00:00
abstract::In the 30 years since the rabbit antithymocyte globulin (rATG) Thymoglobulin(®) was first licensed, its use in solid organ transplantation and hematology has expanded progressively. Although the evidence base is incomplete, specific roles for rATG in organ transplant recipients using contemporary dosing strategies are...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-014-0277-6
更新日期:2014-09-01 00:00:00
abstract::Lapatinib (Tyverb, Tykerb) is an orally active, small molecule, reversible, dual tyrosine kinase inhibitor of human epidermal growth factor receptor type 1 (HER1) and type 2 (HER2). In the EU, lapatinib in combination with capecitabine is indicated for the treatment of women with HER2-overexpressing, advanced or metas...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/11203240-000000000-00000
更新日期:2009-10-22 00:00:00
abstract::Colloid solutions have been developed and used over the past 70 years as expanders of the intravascular space, based on an understanding of Starling's law. Increasing osmotic pressure with colloidal products has remained an attractive theoretical premise for volume resuscitation. Indeed, colloids have been shown to in...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199855050-00002
更新日期:1998-05-01 00:00:00
abstract::Tenoxicam is a new non-steroidal anti-inflammatory and analgesic agent of the oxicam class, and therefore closely related to piroxicam. It possesses a long half-life which enables it to be administered once daily. Clinical trials in patients with rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, gout and n...
journal_title:Drugs
pub_type: 临床试验,杂志文章,评审
doi:10.2165/00003495-198734030-00001
更新日期:1987-09-01 00:00:00
abstract::Antihistamines are a diverse group of drugs which possess the ability to inhibit various histaminic actions. By and large, they bear a certain structural resemblance to histamine, and act principally to prevent histamine-receptor interaction through competition with histamine for histamine receptors. Consequently, the...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-197612040-00002
更新日期:1976-01-01 00:00:00
abstract::When used to treat patients with Parkinson's disease pergolide acts at dopamine receptors in the corpus striatum to improve locomotor activity, reducing the tremor, gait disturbances, bradykinesia or akinesia and rigidity experienced by such patients. Treatment with pergolide often allows substantial reductions in con...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199039030-00009
更新日期:1990-03-01 00:00:00
abstract::Gastric cancer is the seventh and oesophageal cancer the ninth most common cancer in the UK, and >50% of patients present with locally advanced or metastatic disease. The incidence of oesophageal and oesophagogastric junctional tumours is increasing, making these important disease entities to understand and research. ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200767170-00006
更新日期:2007-01-01 00:00:00
abstract::Buflomedil hydrochloride is a vasoactive drug with a variety of pharmacodynamic properties. Importantly, it seems to improve nutritional blood flow in ischaemic tissue of patients with peripheral and/or cerebral vascular disease by a combination of pharmacological effects: inhibition of alpha-adrenoceptors, inhibition...
journal_title:Drugs
pub_type: 临床试验,杂志文章,评审
doi:10.2165/00003495-198733050-00002
更新日期:1987-05-01 00:00:00
abstract::Intravenous susoctocog alfa (Obizur(®)) is a recombinant, B-domain deleted, porcine sequence antihaemophilic factor VIII (FVIII) product that has recently been approved for the treatment of bleeding episodes in adults with acquired haemophilia A (AHA). Intravenous susoctocog alfa was an effective and generally well to...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-016-0576-1
更新日期:2016-05-01 00:00:00
abstract::Nausea and vomiting is a common and distressing symptom complex in patients with far-advanced cancer, affecting up to 60% of individuals at some stage of their illness. The current approach to the palliative care of patients with nausea and vomiting is based on identifying the cause, understanding its pathophysiology ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/0003495-200868180-00004
更新日期:2008-01-01 00:00:00
abstract::Viral conjunctivitis is one of the most common disorders observed in ophthalmic emergency departments, yet no established treatment exists. Lately, antiviral medications have been introduced into clinical practice; however, a systematic review focusing on their use and effectiveness in the treatment of viral conjuncti...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/11585330-000000000-00000
更新日期:2011-02-12 00:00:00
abstract::HMG-CoA reductase inhibitors (statins) have been shown to reduce mortality and cardiovascular morbidity in patients with hyperlipidaemia and those with coronary artery disease. However, evidence for statin treatment in patients with chronic heart failure (CHF) remains a subject of debate. Patients with heart failure w...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200666020-00002
更新日期:2006-01-01 00:00:00
abstract::Long term administration of common loop or distal tubular diuretics may cause somatic magnesium depletion. The resultant deficiency of Mg++ destabilises the myocardium electrically and is a principal cause of cardiac arrhythmias ascribed to diuretics. The adverse effects of diuretics caused by Mg++ depletion can be av...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-198400281-00018
更新日期:1984-10-01 00:00:00
abstract::During recent decades, undeniable progress has been made with regard to the management of arterial hypertension. Larger numbers of patients are aware they have hypertension, receive treatment and benefit from this therapy. Furthermore, significant reductions have been observed in morbidity and mortality resulting from...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199856002-00004
更新日期:1998-01-01 00:00:00